Get SEC filing alerts via email and in your feed for Savara Inc
SVRA
Savara Inc
About Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Its lead program, MOLBREEVI, is an inhaled biologic targeting autoimmune pulmonary alveolar proteinosis (aPAP). The company emphasizes innovative drug delivery, strategic outsourcing, and regulatory engagement to develop and commercialize its treatments, aiming to address unmet medical needs in the rare lung disease market.
This description was generated via AI from an annual report.
Updated 8 months ago.